VEGF inhibitors in metastatic renal cell carcinoma: Current therapies and future perspectives

Current Clinical Pharmacology

Volumn 6, Issue 3, 2011, Pages 164-168

  Choueiri, Toni K ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Renal cell carcinoma; Targeted therapy; VEGF

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR; INTERFERON; INTERLEUKIN 2; LINIFANIB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHONIA; DYSPNEA; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; METASTATIC RENAL CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RASH; SYSTEMIC THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; KIDNEY NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052207998     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411797189424     Document Type: Article

References (38)

1. http://seer.cancer.gov/statfacts/html/kidrp.html. (Accessed February 3, 2011)
2. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13(3): 688-96.
3. McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009; 115(10 Suppl): 2298-305.
4. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; 1: CD001425.
5. Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007; 110(11): 2468-77.
6. Choueiri TK, Hutson TE, Bukowski RM. Evolving role of pegylated interferons in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2003; 3(6): 823-9.
7. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13(2 Pt 2): 680s-4s.
8. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23(5): 965-72.
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-34.
10. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(8): 1280-9.
11. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25(7): 884-96.
12. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. Jama 2006; 295(21): 2516-24.
13. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-24.
14. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-90.
15. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2011; 77(3): 163-71.
16. Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol; 28(3): 475-80.
17. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28(6): 1061-8.
18. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422-8.
19. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-11.
20. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008; 9(6): 658-71.
21. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The lancet oncology 2007; 8(11): 975-84.
22. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27(27): 4462-8.
23. Bhargava P, Esteves B, Al-Adhami M, et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2010; 28(suppl abstr 4599).
24. Angevin E, Lin C, Pande AU. A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results. J Clin Oncol 2010; 28(15_suppl): 3057.
25. Wong CI, Koh TS, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009; 27(28): 4718-26.
26. Tannir N, Wong Y, Kollmannsberger C. Phase II trial of ABT-869 in advanced renal cell cancer (RCCrenal carcinoma) after sunitinib failure: Efficacy and safety results. J Clin Oncol 2009; 27(15S): 5036.
27. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol; 28(5): 780-7.
28. Garcia JA, Hudes GR, Choueiri TK. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12- 0605/NCT00515697). ASCO 2010 Genitourinary Cancers Symposium 2010; p. 326.
29. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99(17): 11393-8.
30. Tew WP, Gordon M, Murren J, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010; 16(1): 358-66.
31. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with me- tastatic renal cell carcinoma. J Clin Oncol 2009; 27(9): 1432-9.
32. Sosman JA, Flaherty KT, Atkins MB, et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008; 26(May 20 suppl; abstr 5011).
33. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7(1): 24-7.
34. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 289-96.
35. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-9.
36. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13(10): 1084-96.
37. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol.
38. Faber PW, Vaziri SA, Wood L, et al. Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib. J Clin Oncol 2008; 26(May 20 suppl; abstr 5009).